Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Expected to Rise, HC Wainwright Analyst Says

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target boosted by equities research analysts at HC Wainwright from $23.00 to $30.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 66.67% from the company’s current price.

A number of other brokerages have also recently issued reports on EYPT. Chardan Capital raised their target price on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada raised their target price on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.50.

Eyepoint Pharmaceuticals Price Performance

Eyepoint Pharmaceuticals stock opened at $18.00 on Thursday. Eyepoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $19.11. The company has a fifty day moving average price of $15.76 and a two-hundred day moving average price of $14.31. The company has a market cap of $1.49 billion, a PE ratio of -6.02 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The business had revenue of $0.62 million during the quarter, compared to the consensus estimate of $1.01 million. Equities research analysts anticipate that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Insider Transactions at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in EYPT. Nisa Investment Advisors LLC grew its stake in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $27,000 after purchasing an additional 2,733 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in Eyepoint Pharmaceuticals in the third quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $76,000. Finally, Tower Research Capital LLC TRC increased its stake in Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after buying an additional 5,967 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

More Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital raised its price target on EYPT to $29 and reiterated a “buy” rating, signaling institutional confidence and implying significant upside versus recent levels. Chardan Price Target Raise
• Positive Sentiment: Company reported >$300M cash & investments at 12/31/25 (runway into Q4 2027), appointed Michael Campbell as Chief Commercial Officer, and said both pivotal Phase 3 DURAVYU trials for wet AMD are on track — all items that improve launch readiness and reduce near‑term financing risk. Press Release
• Positive Sentiment: EyePoint reiterated a mid‑2026 topline data target for DURAVYU in wet AMD and DME as Phase 3 trials advance — a clear near‑term clinical catalyst that can materially re‑rate the stock if data are positive. Topline Timing Article
• Neutral Sentiment: Q4 earnings call transcripts and corporate presentation are available for details on commercial plans, cash runway and trial updates — useful for digging into management’s guidance and launch assumptions. Earnings Call Transcript (Seeking Alpha) Earnings Call Transcript (Yahoo)
• Neutral Sentiment: Short‑interest report posted anomalous/zero values (appears to be data/reporting noise); investors should treat reported large change with caution and check official exchange filings for accurate short interest. (No reliable link provided in the bulletin.)
• Negative Sentiment: Q4 results missed expectations: EyePoint reported a ($0.81) EPS vs. consensus ($0.78) and reported revenue of $0.62M (below some published expectations). The company still shows large negative margins and negative ROE, underscoring current unprofitability ahead of any commercial launch. Earnings Summary / Call Press Release / Financials
• Negative Sentiment: Analyst critique: a Seeking Alpha piece warns the “pre‑readout” rally may be masking commercial execution risks and realistic revenue ramp assumptions — a reminder that positive trial news must translate into durable commercial uptake to justify valuations. Commercial Reality Check

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.